Obsidian Therapeutics
About Obsidian Therapeutics
52 articles about Obsidian Therapeutics
-
Obsidian Therapeutics Appoints Dana Alexander as Chief Technical Officer 5/8/2024 Obsidian Therapeutics，Inc.today announced the appointment of Dana Alexander as Chief Technical Officer。 -
OBX-115，its Engineered TIL Cell Therapy，for Patients with Advanced Solid Tumors in Oral Presentation at the 2024 ASCO Annual Meeting 4/24/2024 Obsidian Therapeutics，Inc.announced two presentations，including an oral presentation on the Phase1first-in-human study of OBX-115，anovel engineered tumor-derived autologous T cell immunotherapy armored with pharmacologically regulatable membrane-bound IL15， in patients with immune checkpoint inhibitor-resistant advanced or metastatic melanoma，at the 2024 American Society of Clinical Oncology Annual Meeting，taking place in Chicago on May31–June4。 -
Obsidian Therapeutics Appoints Jeffrey Trigilio as Chief Financial Officer 4/15/2024 Obsidian Therapeutics，Inc.today announced the appointment of Jeffrey Trigilio as Chief Financial Officer，effective May12024。 -
Obsidian Therapeutics Announces Oversubscribed$160.5 Million Series C Financing to Drive OBX-115 Clinical Development 4/3/2024 Obsidian Therapeutics，Inc.，aclinical-stage biotechnology company pioneering engineered cell and gene therapies，today announced it has closed asignificantly oversubscribed$160.5 million Series C financing with atop-tier syndicate of life science investors led by new investor，Wellingn管理。 -
Obsidian Therapeutics Announces Clinical&Preclinical Presentations at the American Association of Cancer Research Annual Meeting 3/5/2024 Obsidian Therapeutics，Inc.announced presentations reporting initial clinical data from the ongoing first-in-human study of OBX-115and preclinical data from our cytoDRiVE ® platform demonstrating regulatable cytoTIL15signal transduction in cis and trans，as well as the ability of a single DRD to coregulate two cytokines，LIGHT and mbIL15，in tumor-infiltrating lymphocytes during the AACR Annual Meeting，which will be held April5-1024 in San Digo，CA。 -
OBX-115 Engineered TIL Cell Therapy in Advanced or Metatic Melanoma Post-Anti-PD1 Therapy 12/12/2023 Obsidian Therapeutics，Inc.announced today positive top-line results from the ongoing first-in-human，Phase1clical trial evaluating the safety and efficacy of OBX-115。 -
Obsidian Therapeutics Announces Dr.Madan Jagasia as Chief Executive Officer and Other Leadership Appointments 5/23/2023 Company also adds Dr.Parameswaran Hari as Chief Development Officer and appoints Dr.Matthew Norkunas to Board of Directors。 -
Obsidian Therapeutics to Present Preclinical Data from cytoDRiVE ® Platform and Pipeline at Society for Immunotherapy of Cancer（SITC）Annual Meeting 2022 11/7/2022 Obsidian Therapeutics，Inc.，aclinical-stage biotechnology company pioneering engineered cell and gene therapies，today announced it will present preclinical data highlighting its recent cytoDRiVE ® platform and pipeline advances during the poster sessions at the upcoming SITC Annual Meeting 2022。 -
Obsidian Therapeutics Announces Extension of Multi-Year Collaboration Agreement with Bristol Myers Squibb 10/27/2022 Obsidian Therapeutics，Inc.today announced that Bristol Myers Squibb（NYSE:BMY）has opted to extend the term of the parties'multi-year strategic collaboration for the discovery and development of novel，regulated cell therapies that utilize Obsidian's cytoDRiVE ® technology for the controlled expression of the immune enhancer CD40L。 -
FDA Weekly Review looks at the FDA's actions related to drug approvals，IND approvals，designations and more。 Here’salook at what happened this week。 -
D Anderson and Obsidian Therapeutics announce FDA Clearance of IND application for novel TIL therapy OBX-115 7/21/2022 The University of Texas MD Anderson Cancer Center and Obsidian Therapeutics，Inc.today announced Food and Drug Administration（FDA）clearance of an Investigational New Drug（IND）application foran MD Andersonsored Phase I clinical study of OBX-115，Obsidian's lead engineed turmolethery y candidate。 -
Obsidian Therapeutics to Present Significant Advancements to its Proprietary cytoDRiVE ® Technology at the American Society of Gene and Cell Therapy（ASGCT）Annual Meeting 2022 5/17/2022 Obsidian Therapeutics to Present Significant Advancements to its Proprietary cytoDRiVE ® Technology at the American Society of Gene and Cell Therapy（ASGCT）Annual Meeting 2022。 -
Obsidian Therapeutics to Present Preclinical Data from cytoTIL15 ™，™ cancer Research（AACR）Annual Meeting 2022 4/11/2022 Obsidian Therapeutics，Inc.preclinical data high lighting its cytoTIL15 ™，™ program during a poster session at the upcoming AACR Annual Meeting 2022。 -
Obsidian Therapeutics Appoints Maria Fardis，Ph.D.，as Chair of its Board of Directors 1/19/2022 Obsidian Therapeutics，Inc.today announced that Maria Fardis，Ph.D.，has assumed the role of Chair of Obsidian's Board of Directors。 -
As BioSpace proudly introduces our2022 Hotbed Maps，let’s explore the industry’s most thriving territories，research leading employers and search for relevant jobs on BioSpace。 -
BioSpace is marking Martin Luther King，Jr.Day by sharing some of our recent coverage about what the life sciences industry is doing to address racial inequality。 -
Precision Gene Therapy on the Cusp 1/11/2022 The emerging generation of precision gene therapies addresses what has been one of this genre’s greatest challenges to date:the risk of unintended consequences。 -
BioSpace Movers&Shakers，Nov.19 11/19/2021 Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers&Shakers。 -
Obsidian Therapeutics Appoints Heidi Hagen to Board of Directors 11/16/2021 Obsidian Therapeutics，Inc.，abiotechnology company pioneering engineered cell and gene therapies，announced the appointment of Heidi Hagen to its Board of Directors。 -
Obsidian Therapeutics to Present Invivo Anti-Tumor Efficacy Data from Novel Engineered cytoTIL15 Program at SITC 2021 11/9/2021 Obsidian Therapeutics，Inc.，abiotechnology company pioneering engineered cell and gene therapies，today announced that the Company will present preclinical in vivo anti-tumorefficacy against melanoma data for its cytoTIL15 ™，™ program at the upcoming Annual Meeting of the Society for Immunotherapy of Cancer（SITC）。